LNZ IV 600 Infusion contains Linezolid 600 mg, an oxazolidinone-class antibiotic indicated for the treatment of serious Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE). Administered intravenously, Linezolid inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the initiation complex essential for bacterial translation. LNZ IV 600 is primarily used in hospital settings for complicated skin and soft tissue infections, nosocomial pneumonia, and other severe infections where oral administration is not feasible. The infusion should be administered over 30 to 120 minutes, with dosing adjustments considered in patients with renal or hepatic impairment. Monitoring for potential adverse effects such as myelosuppression, peripheral and optic neuropathy, and serotonin syndrome is recommended during prolonged therapy. Caution is advised when co-administered with serotonergic agents or monoamine oxidase inhibitors. LNZ IV 600 offers a valuable therapeutic option for multidrug-resistant infections, providing effective bacteriostatic activity against a broad spectrum of resistant Gram-positive pathogens. Proper aseptic technique and adherence to dosing guidelines are essential to optimize clinical outcomes and minimize resistance development.